MAP Patient Access Limited
Jo Wallis is a highly experienced professional in the pharmaceutical industry, with expertise in market access, pricing strategy, and health technology assessment operations. They have held various leadership roles at Pfizer, specializing in Rare Diseases and Anti-Infectives portfolios. With a background in psychology and a post-graduate certificate in health economic evaluation, Jo has a strong analytical skill set and proven ability to communicate effectively with key stakeholders in the healthcare industry. Their track record includes successful product launches and national recognition for performance excellence.
MAP Patient Access Limited
MAP is the Market Access specialist for innovative technologies. We help companies overcome the most challenging access issues, especially when they are due to rarity or complexity. Drawing on over a decade’s worth of experience, MAP works with ambitious biopharma companies wishing to launch in the UK and Europe. Our unique integrated approach helps you navigate the complexities of the market access, pricing and reimbursement landscape. With offices in England and Europe, our expertise spans over 20 markets and makes us the partner of choice for facilitating successful market access in Europe. Our services include: • Consultancy – we are a market-leading integrated consultancy that covers patient and political engagement, pricing and reimbursement strategy, HTA submissions, HEOR, value communication, and legal insights. Our team give you answers that take the big picture into account, whilst still allowing you to focus your consultancy spend where it will have the most impact. • Membership – members can benefit from our expertise through a unique blend of unlimited support from our experienced team, combined with our online knowledge portal bursting with up-to-date resources. Membership is designed to help our members free up valuable time and resource by utilising our team of experts as an extension of their own team. This blended approach creates competitive advantage for our clients and has resulted in over 95% positive outcomes on client projects. Our team draw on deep experience from across the industry and have supported over 200 successful HTA and pricing applications. Not only were 70% of NICE HST’s supported by MAP, but we were also responsible for the fastest ever HST approval. LEARN MORE www.mappatientaccess.com and book a scoping call with a Market Access expert to explore how we can help. Email: enquiries@mappatientaccess.com